

THOMSON

DELPHION

Tracking No Active T

Select



RESEARCH

PRODUCTS

INSIDE DELPHION

My Account

Search: Quick/Number Boolean Advanced Derwent

The Delphion Integrated View: INPADOC Record

Buy Now: ☒ PDF | [More choices...](#)Tools: Add to Work File: [Create new Work File](#)View: Jump to: [Top](#)Go to: [Derwent](#)☐ Email

Title: **FR2688514A1: ADENOVIRUS RECOMBINANTS DEFECTIFS EXPRIMANT DES CYTOKINES ET MEDICAMENTS ANTITUMORAUX LES CONTENANT**

Derwent Title: New defective recombinant adenovirus contg. cytokine gene - but incapable of replication, useful as directly injectable antitumour agent ([Derwent Record](#))

Country: FR France

Kind: A1 Application, First Publication

Inventor: **HADDADA HEDI;
RAGOT THIERRY;
PERRICAUDET MICHEL;**



Assignee: **CENTRE NATIONAL RECHERCHE SCIENTIFIQUE** France
[News](#), [Profiles](#), [Stocks](#) and [More about this company](#)

Published / Filed: 1993-09-17 / 1992-03-16

Application Number: FR1992009203120

IPC Code: **C12N 7/01; C12N 15/87; A61K 48/00;**

ECLA Code: None

Priority Number: 1992-03-16 FR1992009203120

INPADOC
Legal Status:

Gazette date	Code	Description (remarks)	List all possible codes for FR
1993-12-24	TP	Transmission of property	

Buy Now: [Family Legal Status Report](#)

Designated
Country: AU CA EP FI HU JP NO NZ US

Family:

Buy PDF	Publication	Pub. Date	Filed	Title
<input type="checkbox"/>	WO9319191A1	1993-09-30	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR USE IN ANTITUMORAL TREATMENT
<input type="checkbox"/>	US20020031499A1	2002-03-14	1998-12-03	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	SG0049002A1	1998-05-18	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	PT0593755T	2002-03-28	1993-03-16	ADENOVIRUS RECOMBINANTES DEFECTIVOS QUE EXPRESAN




				CITOQUINAS PARA O TRATAMENTO ANTITUMORAL
<input checked="" type="checkbox"/>	NZ0255950A	1996-03-26	1993-03-16	RECOMBINANT ADENOVIRUSES EXPRESSING CYTOKINES, ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	NO0934061A0	1993-11-09	1993-11-09	DEFEKTIVE REKOMBINANT ADENOVIRUS SOM EKSPRIMERER CYTOKINER ANVENDELSE VED ANTI-TUMOR-BEHANDLING
<input checked="" type="checkbox"/>	NO0934061A	1993-11-09	1993-11-09	DEFEKTIVE REKOMBINANT ADENOVIRUS SOM EKSPRIMERER CYTOKINER ANVENDELSE VED ANTI-TUMOR-BEHANDLING
<input checked="" type="checkbox"/>	JP06508039T2	1994-09-14	1993-03-16	
<input checked="" type="checkbox"/>	JP03422995B2	2003-07-07	1993-03-16	
<input checked="" type="checkbox"/>	HU9303229A0	1994-03-28	1993-03-16	APPLICATION OF DEFICIENT RECOMBINANT ADENOVIRUSES EXPRESSING CYTOKINES FOR ANTITUMOUR TREATMENT
<input checked="" type="checkbox"/>	HU0221275B1	2002-09-28	1993-03-16	REPLICATION DEFECTIVE RECOMBINANT ADENOVIRUSES EXPRESSING ANTIMETASTATIC CYTOKINES, PROCESS FOR PRODUCTION THEREOF AND THEIR USES
<input checked="" type="checkbox"/>	HU0066486A2	1994-11-28	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR USE IN ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	FR2688514B1	1994-12-30	1992-03-16	
<input checked="" type="checkbox"/>	FR2688514A1	1993-09-17	1992-03-16	ADENOVIRUS RECOMBINANTS DEFECTIFS EXPRIMANT DES CYTOKINES ET MEDICAMENTS ANTITUMORAUX LEUR CONTENANT.
<input checked="" type="checkbox"/>	FI0935058A0	1993-11-16	1993-11-16	FOER ANTITUMORERBEHANDLING REKOMBINANT-ADENOVIRUS SOM UTTRYCKER CYTOKINER
<input checked="" type="checkbox"/>	FI0935058A	1994-01-14	1993-11-16	FOER ANTITUMORERBEHANDLING REKOMBINANT-ADENOVIRUS SOM UTTRYCKER CYTOKINER
<input checked="" type="checkbox"/>	ES2164669T3	2002-03-01	1993-03-16	ADENOVIRUS RECOMBINANTES DEFECTIVOS QUE EXPRESAN CITOQUINAS PARA TRATAMIENTO ANTITUMORAL
<input type="checkbox"/>	EP1138774A2	2001-10-04	1993-03-16	Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment
<input type="checkbox"/>	EP0593755B1	2001-09-19	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR USE IN ANTITUMORAL TREATMENT
<input type="checkbox"/>	EP0593755A1	1994-04-27	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR USE IN ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	DK0593755T3	2001-12-31	1993-03-16	ADENOVIRUS, SOM ER DEFEKT REPLIKATION, OG SOM UDTRYKKER CYTOKINER, TIL ANTITUMORBEHANDLING
<input checked="" type="checkbox"/>	DE69330774T2	2002-07-04	1993-03-16	CYTOKIN EXPREMIERENDER DEFECTIVE REKOMBINANTER ADENOVIRUS II VERWENDUNG BEI DER ANTITUMORAL BEHANDLUNG
				CYTOKIN EXPREMIERENDER DEFECTIVE REKOMBINANTER ADENOVIRUS II VERWENDUNG BEI DER ANTITUMORAL BEHANDLUNG

<input checked="" type="checkbox"/>	DE69330774C0	2001-10-25	1993-03-16	REKOMBINANTER ADENOVIRUS II VERWENDUNG BEI DER ANTITUMOR- BEHANDLUNG
<input checked="" type="checkbox"/>	CA2102302C	2003-05-20	1993-03-16	RECOMBINANT DEFECTIVE ADENOVIRUS EXPRESSING CYTOKINES FOR AN ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	CA2102302AA	1993-09-17	1993-03-16	
<input checked="" type="checkbox"/>	AU3757093A1	1993-10-21	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR USE IN ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	AU0672195B2	1996-09-26	1993-03-16	DEFECTIVE RECOMBINANT ADENOVIRUS EXPRESSING CYTOKINES FOR USE IN ANTITUMORAL TREATMENT
<input checked="" type="checkbox"/>	AT0205883E	2001-10-15	1993-03-16	CYTOKIN EXPREMIERENDER DEFECTIVER REKOMBINANTER ADENOVIRUS II VERWENDUNG BEI DER ANTITUMOR- BEHANDLUNG
28 family members shown above				

Forward
References:

Go to Result Set: Forward references (13)

Buy PDF	Patent	Pub.Date	Inventor	Assignee	Title
<input type="checkbox"/>	US6805858	2004-10-19	Zhang; Wei-Wei	Board of Regents, The University of Texas System	Methods for the ad- ministration of adenovirus p53
<input type="checkbox"/>	US6797702	2004-09-28	Roth; Jack A.	Board of Regents, The University of Texas System	Methods and compo- sitions comprising DNA de- livery agents and P53
<input type="checkbox"/>	US6685934	2004-02-03	Mallet; Jacques	Aventis Pharma S.A.	Recombinant adenovirus coding for basic fibroblast growth factors (BFGF)
<input type="checkbox"/>	US6627189	2003-09-30	Roth; Jack A.	Board of Regents, The University of Texas Systems	Inhibition of cellular proliferation using r- antisense molecule
<input type="checkbox"/>	US6511847	2003-01-28	Zhang; Wei-Wei	Board of Regents, The University of Texas System	Recombinant p53 ex- pressing vectors and methods and compo-
<input type="checkbox"/>	US6436700	2002-08-20	Roth; Jack A.	Board of Regents, The University of Texas Systems	Anti-sense p21 k-ras expression vectors and methods and compo-
<input type="checkbox"/>	US6410029	2002-06-25	Mukhopadhyay; Tapas	Board of Regents, The University of Texas System	2-methoxyestradiol induced apoptosis in cancer
<input type="checkbox"/>	US6245330	2001-06-12	Horellou; Philippe	Aventis Pharma S.A.	Recombinant adenovirus coding for glial-deri- vative neurotrophic factor
<input type="checkbox"/>	US6143290	2000-11-07	Zhang; Wei-Wei	The Board of Regents, University of Texas System	Tumor regression by adenovirus expres- sion of type p53
<input type="checkbox"/>	US6069134	2000-05-30	Roth; Jack A.	Board of Regents, The University of Texas System	Methods and compo- sitions comprising DNA de- livery agents and p53

	US6017524	2000-01-25	Roth; Jack A.	Board of Regents, The University of Texas System	Inhibiting the growth of deficient tumor cells by administering the p
	US5932210	1999-08-03	Gregory; Richard J.	Canji Inc.	Recombinant adenoviral vector and method of
	US5747469	1998-05-05	Roth; Jack A.	Board of Regents, The University of Texas System	Methods and compositions comprising DNA constructs and p53

Other Abstract
Info:

None



Nominate this for the Gall



Copyright © 1997-2004
The Thomson Corporation

[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#)